Methylprednisolone liposomal - 2-BBB Medicines

Drug Profile

Methylprednisolone liposomal - 2-BBB Medicines

Alternative Names: 2B3-201; Brain-targeted methylprednisolone - 2-BBB Medicines; Glutathione PEGylated-liposomal methylprednisolone - 2-BBB Medicines

Latest Information Update: 22 Sep 2016

Price : $50

At a glance

  • Originator to-BBB technologies
  • Developer 2-BBB Medicines
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antirheumatics; Glucocorticoids; Pregnadienetriols
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple sclerosis
  • Preclinical CNS disorders

Most Recent Events

  • 22 Sep 2016 Phase I development in Multiple sclerosis is ongoing in the Netherlands (IV) (2-BBB Medicines pipeline, September 2016)
  • 22 Sep 2016 Preclinical development in CNS-disorders is ongoing in Netherlands (IV, Liposomal) (2-BBB Medicines pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in Netherlands (IV, Liposomal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top